ISCG vs. RZG: Which Small-Cap Growth ETF Is the Better Buy for Investors?

ISCG (iShares Morningstar Small-Cap Growth) charges a 0.06% expense ratio versus RZG’s 0.35% (about $6 vs ~$35 annually on a $10,000 investment), with a slightly higher dividend yield (0.57% vs 0.42%). Over the past year, RZG delivered 38.84% total return vs ISCG’s 27.53%, though ISCG is more diversified (933 holdings vs 125). RZG’s outperformance is attributed to its more concentrated focus on sales/earnings/price momentum, while ISCG trades some upside for broader small-cap growth exposure.

Analysis

This is mainly a factor-implementation trade, not a fresh fundamental catalyst. The concentrated product is effectively a levered bet on a handful of momentum-rich small caps, so it should outperform only while earnings revisions and risk appetite stay synchronized; that creates upside torque, but also makes the vehicle vulnerable to one or two misses. The broader, cheaper vehicle should be the better long-horizon wrapper for allocators because the fee gap compounds and the diversification reduces the odds that a single drawdown derails the sleeve.

The immediate battleground is flow, not valuation. If small-cap growth stays in favor, liquidity will first chase the names with existing momentum and better index visibility, which benefits the concentrated basket’s top holdings and can spill into the underlying equities. But that same concentration makes the trade fragile: any reversal in rates, a broadening out of market leadership, or a couple of earnings downgrades can cause relative underperformance fast, while the lower-beta, more diversified structure should hold up better in a choppier tape.

The contrarian point is that recent outperformance may be a backward-looking momentum premium rather than a durable edge after fees. Consensus is treating the concentrated product as a superior expression of the theme, but for most mandates the better risk-adjusted solution is probably the cheaper diversified sleeve, with the concentrated one reserved for tactical exposure only. The thesis breaks if small-cap growth continues to see positive estimate revisions and the market rewards concentration through the next earnings cycle; it improves for the diversified sleeve if breadth widens or real rates back up.

Key Decisions for Investors

• Long ISCG / short RZG on a 3-6 month horizon as a beta-neutral relative-value trade; thesis is that fee drag and concentration risk should erode the concentrated basket’s recent edge. Falsifier: sustained earnings upside in ACMR, POWL, STRL, and OKTA keeps the momentum basket in the lead.
• Use ISCG as the default core allocation for small-cap growth exposure over 6-18 months; the lower expense ratio and broader diversification should matter more than recent performance once factor leadership normalizes. Risk: underperform if the market remains in a narrow momentum regime.
• If you want tactical upside, own RZG only on pullbacks after a sharp relative selloff versus ISCG, with a 1-3 month trade horizon. This is a momentum continuation bet, not a core hold; take profits if relative outperformance extends and breadth narrows.
• Set an alert on the top concentrated holdings (ACMR, POWL, STRL, AGX, GH, OKTA): if two or more guide down or miss on revisions, rotate out of RZG and favor ISCG immediately.